| abstract |
The present invention relates to include following pharmaceutical composition：(a) 3 kinase inhibitor of phosphatidylinositols or its pharmaceutically-acceptable salts, (b) at least one c Met receptor tyrosine kinase inhibitors or its pharmaceutically-acceptable salts, for simultaneously, separately or sequentially applying to treat proliferative diseases, particularly c Met dependences proliferative diseases；Include the pharmaceutical composition of the combination；The method of object of the treatment with proliferative diseases, the method includes applying the combination to object in need；Purposes of the combination in proliferative diseases are treated；And the commercial package comprising the combination. |